Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration.
about
siRNA Delivery by Stimuli-Sensitive NanocarriersBench-to-bedside translation of magnetic nanoparticlesMechanisms and implications of dual-acting methotrexate in folate-targeted nanotherapeutic deliveryMultifunctional nanoparticles for brain tumor imaging and therapy.Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapyTriple-Modal Imaging of Magnetically-Targeted Nanocapsules in Solid Tumours In Vivo.Iron oxide nanoparticles for magnetically-guided and magnetically-responsive drug deliveryIn vitro genotoxicity testing strategy for nanomaterials and the adaptation of current OECD guidelinesMagnetic Nanoparticle Facilitated Drug Delivery for Cancer Therapy with Targeted and Image-Guided ApproachesTheranostic Magnetic Nanostructures (MNS) for Cancer.Application of iron oxide nanoparticles in glioma imaging and therapy: from bench to bedside.Magnetic tumor targeting of β-glucosidase immobilized iron oxide nanoparticles.Enhanced and selective delivery of enzyme therapy to 9L-glioma tumor via magnetic targeting of PEG-modified, β-glucosidase-conjugated iron oxide nanoparticles.Theranostic nanoparticles based on bioreducible polyethylenimine-coated iron oxide for reduction-responsive gene delivery and magnetic resonance imagingSuperparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeuticsMagnetic nanoparticles for tumor imaging and therapy: a so-called theranostic system.FGF receptor-mediated gene delivery using ligands coupled to PEI-β-CyD.Altering iron oxide nanoparticle surface properties induce cortical neuron cytotoxicity.Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting.MC8 peptide-mediated Her-2 receptor targeting based on PEI-β-CyD as gene delivery vector.A combined theoretical and in vitro modeling approach for predicting the magnetic capture and retention of magnetic nanoparticles in vivo.Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers.Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticlesHyaluronic acid-modified magnetic iron oxide nanoparticles for MR imaging of surgically induced endometriosis model in ratsCancer theranostics: the rise of targeted magnetic nanoparticles.Influences of surface coatings and components of FePt nanoparticles on the suppression of glioma cell proliferationMagnetic nanoparticles as targeted delivery systems in oncology.In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticlesAntitumor activity of dichloroacetate on C6 glioma cell: in vitro and in vivo evaluation.Folic acid-targeted iron oxide nanoparticles as contrast agents for magnetic resonance imaging of human ovarian cancerPotential of magnetic nanoparticles for targeted drug deliveryLong-circulating heparin-functionalized magnetic nanoparticles for potential application as a protein drug delivery platform.Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION-EGF) for targeting brain tumors.The nanomaterial toolkit for neuroengineering.Magnetic targeting of novel heparinized iron oxide nanoparticles evaluated in a 9L-glioma mouse model.Current status of gene delivery: spotlight on nanomaterial-polymer hybrids.Cationic polymers and their therapeutic potential.Bibliometric analysis of nanotechnology applied in oncology from 2002 to 2011.Inorganic nanovectors for nucleic acid delivery.Polyethylenimine-based micro/nanoparticles as vaccine adjuvants.
P2860
Q26781212-2D2202BC-4382-4796-87C2-F8D6DF13DA1DQ26850547-5E607E16-457F-4D8A-A72C-ED0D40E16051Q26852723-5FF31EC8-915A-47BA-8B0E-57C77F829050Q26865418-0AE48C5D-65EF-48A8-A7FB-E36827D969DDQ27004205-8BDA346E-3D3D-44F5-B4EB-AA68C0425C0AQ27300994-3CF2F772-5CC1-4350-9E4D-631D62862447Q28085546-99CA31BA-D834-4D4E-A98E-0D3D967137C2Q28386315-8D31D964-5105-4F85-B0CA-D0E36035464BQ30354223-0E1941DC-85AC-48FA-9757-32F2503BBF9CQ30937214-AACB34A3-41CB-4C44-B310-EA0FCC96C138Q31065446-14D0E8D4-5F05-4FB1-B857-421FA7C8905FQ33688825-D027A3EA-1188-4586-8B64-3DB2BE7175EFQ33769441-9F1366DA-E3B9-4101-B145-9B6217134C96Q33906003-BF066BE1-8699-4AFB-9B72-9FBC70D20CFCQ34205366-35FD72A4-D21B-49E2-AFCA-5E56ADDF986FQ34229309-2055DC9B-1358-4FAC-8E8A-F37F09639E31Q34262949-923447B5-D522-4B5A-ABC0-3E013438DFC7Q34280319-3BEA5FFF-F282-44DD-8319-61A1C1C0CB7BQ34500552-3A1E1F7B-FD7F-4831-84F3-CFAC9F3EF366Q34504629-70C9120F-872E-40F1-B11A-F61CA8394A48Q35037158-66BE04B4-AFF3-446C-BC5F-C79130DB63C8Q35087596-3B169DBF-EC81-4508-91E2-ABEC1D42B681Q35087646-62E2EB26-EDF7-4F7B-ACAD-0FB57640B378Q35145241-E0395FA0-4BFF-4AD6-8A89-B1F9280DE349Q35533813-5ED86103-ADA7-498A-9287-25B57F7482F6Q36119558-0575F5FC-A883-490E-8EAF-8FFB5E427C99Q36177729-4FBAA7F5-1066-4C76-A560-96BCFDC26DBDQ36289257-79362D43-E9E3-4259-9A4C-363F6EAA072FQ36694593-60FC07FF-FDCF-4E21-BA15-8798DD839BA8Q36742449-0C8A53DC-023A-4254-9401-C6D4C9AC6B9CQ37194054-2B35A13B-E54D-4FA5-B5B0-A522CA6287E2Q37267350-6D91E1A7-EC9B-46F9-B8AA-3DBE8CCC99A4Q37464021-4931A76F-C3AC-4A25-9779-6F38506C8F25Q37610362-A5F61536-6A26-466E-A76D-1CD195786092Q37619920-3FABD7E1-D172-4B2E-A33A-8A4A08E22AADQ38026945-A87E6376-4293-4217-AD8F-FA44403F97E4Q38033969-077A8E9D-B8E3-4936-8C20-845DE3F58364Q38130139-B74F711E-3D8F-49A9-9E29-F4ECD27C5F28Q38383483-98A8DF39-53C9-449D-936F-E0065DA781C8Q38641439-DC4992DD-66D1-45FE-8B4B-5AEAF73AEE99
P2860
Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Polyethyleneimine-modified iro ...... intra-carotid administration.
@ast
Polyethyleneimine-modified iro ...... intra-carotid administration.
@en
type
label
Polyethyleneimine-modified iro ...... intra-carotid administration.
@ast
Polyethyleneimine-modified iro ...... intra-carotid administration.
@en
prefLabel
Polyethyleneimine-modified iro ...... intra-carotid administration.
@ast
Polyethyleneimine-modified iro ...... intra-carotid administration.
@en
P2093
P2860
P921
P1433
P1476
Polyethyleneimine-modified iro ...... intra-carotid administration.
@en
P2093
Allan E David
Beata Chertok
Victor C Yang
P2860
P304
P356
10.1016/J.BIOMATERIALS.2010.04.043
P577
2010-05-21T00:00:00Z